title: Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer.
abstract: OBJECTIVE
  This retrospective study was designed to evaluate the efficacy and safety of Paclitaxel (PTX) combined with Oxaliplatin (OXA) as first-line chemotherapy for locally advanced or metastatic gastric cancer (AGC).
  
  
  METHODS
  Untreated patients with histologically confirmed AGC who received PTX at 135 mg/m(2) and OXA at 85 mg/m(2) every 2 weeks were studied. Antitumor activity was assessed by imaging and toxicities were evaluated.
  
  
  RESULTS
  Thirty-nine (39) patients were enrolled. With 9.83 months median time of follow-up, 1 year OS rate was 42.0%. Complete response, partial response, stable disease and progressive disease was 2.6, 66.7, 17.9 and 12.0% respectively, the overall response rate was 69.2%. The mPFS was 8.5 months and the mOS 14.4 months. Grade 3/4 of toxicities included neutropenia (38.5%), febrile neutropenia (20.5%), vomiting (7.7%) and hypertransaminasemia (7.7%). Grade 2 peripheral neuropathy occurred in 33.3% patients.
  
  
  CONCLUSIONS
  The combination of PTX combined with OXA is an active and safe regime for AGC and has a high overall response rate.
authors.affiliation: Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian PR, China.
authors.forename: Chunmei
authors.initials: C
authors.lastname: Shi
authors.forename: Qiang
authors.initials: Q
authors.lastname: Chen
authors.forename: Songfei
authors.initials: S
authors.lastname: Shen
authors.forename: Riping
authors.initials: R
authors.lastname: Wu
authors.forename: Baoyu
authors.initials: B
authors.lastname: Yang
authors.forename: Qing
authors.initials: Q
authors.lastname: Liu
authors.forename: Qian
authors.initials: Q
authors.lastname: Xu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D017239:Paclitaxel
keywords: advanced gastric cancer; chemotherapy; first-line; oxaliplatin; paclitaxel